Skip to content
10-Q

Quarterly Report

Nugenerex Immuno-oncology, Inc.

0001607062-21-000156

← back to feed
Filed
Jun 14, 2021 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Jun 14, 2021 100.3M sh
Stockholders Equity Q3 2021 · Apr 30, 2021 −$8.57M
Stockholders Equity Q3 2021 · Jan 31, 2021 −$6.61M
Stockholders Equity Q3 2021 · Oct 31, 2020 −$6.01M
Stockholders Equity Q3 2021 · Jul 31, 2020 −$5.84M
Stockholders Equity Q3 2021 · Apr 30, 2020 −$5.4M
Stockholders Equity Q3 2021 · Jan 31, 2020 −$5.13M
Stockholders Equity Q3 2021 · Oct 31, 2019 −$4.84M
Stockholders Equity Q3 2021 · Jul 31, 2019 −$4.38M
Current Liabilities Q3 2021 · Apr 30, 2021 $13.72M
Current Liabilities Q3 2021 · Jul 31, 2020 $5.84M
Current Assets Q3 2021 · Apr 30, 2021 $5.15M
Current Assets Q3 2021 · Jul 31, 2020 $84
Sga Expense Q3 2021 · Apr 30, 2021 $633.04K
Sga Expense Q3 2021 · Apr 30, 2021 $1.73M
Sga Expense Q3 2021 · Apr 30, 2020 $88.71K
Sga Expense restated Q3 2021 · Apr 30, 2020 $200.56K
Rd Expense Q3 2021 · Apr 30, 2021 $1.06M
Rd Expense Q3 2021 · Apr 30, 2021 $3.3M
Rd Expense Q3 2021 · Apr 30, 2020 $255.27K
Net Income Q3 2021 · Apr 30, 2021 −$1.96M
Net Income Q3 2021 · Apr 30, 2021 −$5.78M
Net Income Q3 2021 · Apr 30, 2020 −$307.07K
Net Income Q3 2021 · Apr 30, 2020 −$1.08M